Co-morbidity influenced CHF management by masking CHF's early stages, causing late diagnosis [50] and complicating patients' attempts to manage their illness, in particular lifestyle changes and diet [40,48]; and increasing risks of undesired pharmacological interactions and adverse effects of medications, ACE inhibitors and beta-blockers [40]. This evidence concerns the gene ACE and congestive heart failure.